Prototype Anionic
Detergent Technique Used to Decellularize Allograft Valve Conduits Evaluated
in the Right Ventricular Outflow Tract in Sheep
Stephen L. Hilbert, Roh Yanagida, Jason Souza, Lloyd Wolfinbarger,
Alyce Linthurst Jones, Paula Krueger, Gary Stearns, Arthur Bert, Richard
A. Hopkins
Office of Science and Engineering Laboratories,
Center for Devices and Radiological Health, Food and Drug Administration,
Rockville, MD, Collis Cardiac Surgical Research Laboratory, Rhode
Island Hospital, and Brown Medical School, Division of Cardiothoracic
Surgery, Department of Surgery, Providence, RI, LifeNet, Virginia
Beach, AV, USA |
Background and aim of the study: Biodegradable
polymeric materials or extracellular matrix scaffolds are used in tissue-engineered
heart valve designs, with the expectation of replicating the anatomic,
histological and biomechanical characteristics of semilunar valves. The
study aim was to evaluate the extent of in-vivo recellularization and
the explant pathology findings of a prototype anionic, non-denaturing
detergent and endonuclease technique used to decellularize allograft
(homograft) valve conduits implanted in the right ventricular outflow
tract (RVOT) of sheep, and to identify possible risks associated with
tissue-engineered heart valve conduits based on decellularized allograft
semilunar valve scaffolds.
Methods: Valve conduits were decellularized using a solution
of N-lauroylsarcosinate and endonucleases, rinsed in lactated Ringers
solution, and stored in an antibiotic solution at 4∞C until
implanted. Explanted valves and unimplanted controls were examined
macroscopically, radiographically (for calcification) and histologically
using immunohistochemistry (IHC), routine and special histological
stains, transmission electron microscopy (TEM) and polarized light
microscopy (evaluation of collagen crimp).
Results: Cells and cellular remnants were uniformly absent
in the decellularized cusps, but occasional focal sites of arterial
wall smooth muscle cells and to a greater extent subvalvular cardiac
myocytes were variably retained. The trilaminar histological structure
of the cusp was preserved. Valve |
conduit-related pathology consisted of intracuspal hematoma
formation, collagen fraying, thinning of the conduit wall, and inflammatory
cells associated with cardiac myocyte remnants. Cuspal calcification
was not seen, but elastic fibers in the conduit wall and retained subvalvular
cardiac myocyte remnants were liable to calcification. Fibrous sheath
formation was present on the luminal surface of the conduit and extended
over the cuspal surfaces to a variable extent. Myofibroblast-like cells
repopulated the conduit wall and the basal region of the cusp. Re-endothelialization
was variably present on the cuspal surfaces.
Conclusion: Explant pathology findings showed that in-vivo
recellularization occurred, but was focally limited to regions
of the arterial wall and cusp base. Safety concerns related to
detergent and endonuclease use were identified. Methods to eliminate
the potential for structural deterioration and enhance the rate
and extent of recellularization of valve conduit tissue are required.
Pathology findings showed implantation of valve conduits in the
RVOT of juvenile sheep for 20 weeks to be a reliable animal model
for the initial in-vivo assessment of decellularized valves. A
20-week period may be insufficient however to evaluate the long-term
safety and effectiveness of a tissue-engineered valve conduit,
as these depend on effective and phenotypically appropriate recellularization
accompanied by sustained cell viability and function.
The Journal of Heart Valve Disease 2004;13:831-840 |